CD39/CD73 Axis Inhibition for T Cell Restoration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for targeting CD39 and CD73 in cancer treatment are limited in effectively reducing adenosine generation, with antibodies often showing partial inhibition and complex interactions that hinder evaluation of their underlying activity.
Innovation Solution
Administering antibodies that specifically bind and inhibit the ATPase activity of soluble CD39, in combination with agents that inhibit CD73, to disrupt the CD39/CD73 axis, thereby reducing immunosuppression and enhancing anti-tumor immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If antibodies are used to target CD73, then selectivity for CD73 is improved, but enzymatic activity inhibition is partial and complex interactions complicate evaluation
Solution Approach 1:
The patent segments the CD39/CD73 axis into two separate targetable components and develops specific inhibitors for each. By targeting CD39 with a small molecule inhibitor and CD73 with an antibody, the patent achieves complete inhibition of adenosine generation through distinct mechanisms of action, avoiding the partial inhibition seen with single-target approaches.
Solution Approach 2:
The patent combines CD39 inhibition (via small molecule) and CD73 inhibition (via antibody) into a synergistic therapy. This combination merges two different inhibitory mechanisms to achieve complete blockade of the CD39/CD73 axis, resulting in dramatic reduction of immunosuppression that neither agent could achieve alone.
2Quantity of substance
If CD39 is targeted with antibodies, then CD39 binding is achieved, but enzymatic activity is not fully inhibited and soluble CD39 forms complicate the picture
Solution Approach 1:
The patent replaces the antibody-based mechanical binding approach with a small molecule inhibitor that directly blocks the enzymatic active site of CD39. This chemical mechanism provides complete inhibition of ATP hydrolysis activity, overcoming the limitations of antibody binding that does not fully prevent enzymatic function or account for soluble CD39 forms.
3Object-generated harmful factors
If CD73 inhibition is used alone, then adenosine generation is partially reduced, but T cell activity remains suppressed
Solution Approach 1:
The patent applies preliminary anti-action by inhibiting CD39 before CD73, thereby preventing the formation of AMP (the substrate for CD73) in the first place. This upstream blockade complements the downstream CD73 inhibition, creating complete prevention of adenosine generation and reliable restoration of T cell activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach leads to a dramatic reduction in immunosuppression and substantially complete inhibition of the catabolic activity of the CD39/CD73 axis, enhancing anti-tumor immunity by conserving ATP and reducing adenosine levels in the tumor microenvironment.
Implementation Method 1
functions together with another enzyme, CD73 (ecto-5'-nucleotidase), to hydrolyze extracellular adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to generate adenosine
Implementation Method 2
CD73 catalyzes the conversion of AMP to adenosine
Implementation Method 3
an antibody that binds and inhibits the ATPase activity of a soluble extracellular domain CD39, and an antibody that neutralizes the 5' ectonuclease activity of human CD73
Data Source
Figure 1
Figure 2A~2B
Figure 3A
AI summary
The present invention relates to methods of using compounds that inhibit the enzymatic activity of soluble human CD39 to treat cancer, including but not limited to the treatment of cancers characterized by CD73 expressing cells.